People with inflammatory bowel disease treated with vedolizumab monotherapy are almost half as likely as those who take anti–tumor necrosis factor monotherapy to experience serious infections and serious adverse events, new findings have shown. Vedolizumab (Entyvio, Takeda Pharmaceuticals) also was more effective than anti-TNF drugs in inducing clinical, steroid-free and endoscopic remission at one year, particularly in patients with Crohn’s disease with colonic disease.
The results,